Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
October 29, 2020 17:16 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing...
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
October 29, 2020 17:15 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2020 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum to Participate in Two Upcoming Virtual Conferences
September 28, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2020 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Inc. Magazine Unveils Its Annual List of America’s Fastest-Growing Private Companies—the Inc. 5000
August 12, 2020 09:00 ET
|
Liquipel Assurance LLC
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Inc. magazine today revealed that Liquipel is on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private...
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
August 06, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 ...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 30, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...